Acta Med. 2002, 45: 29-32

https://doi.org/10.14712/18059694.2019.53

Troponins in Experimental Studies

Michaela Adamcováa, Vladimír Geršlb, Jarmila Macháčkováb, Radomír Hrdinac, Ivona Klimtovác, Tomáš Šimůnekc, Jaroslava Vávrovád, Josef Bukače

aCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Physiology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology and Toxicology, Hradec Králové, Czech Republic
dUniversity Hospital in Hradec Králové: Institute of Clinical Biochemistry and Diagnosis, Hradec Králové, Czech Republic
eCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Biophysics, Hradec Králové, Czech Republic

Received March 1, 2002
Accepted April 1, 2002

References

1. Adamcová M, Geršl V, Hrdina R, Palička V, Mazurová Y. Contribution to prediction and pathogenesis of daunorubicin-induced cardiomyopathy in rabbits. Exp Clin Cardiol 1998; 3(3):179–83.
2. Adamcová M, Geršl V, Hrdina R et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 1999; 125(5):268–74.
3. Apple FS. The specificity of biochemical markers of cardiac damage: a problem solved. Clin Chem Lab Med 1999; 37(11/12):1085–9. <https://doi.org/10.1515/CCLM.1999.158>
4. Boucek RJ, Dodd DA, Atkinson JB, Oquist N, Olson RD. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 1997; 29(10): 2631–40. <https://doi.org/10.1006/jmcc.1997.0494>
5. Czarnecki CM. Animal models of drug-induced cardiomyopathy. Comp Biochem Physiol 1984; 79C/1:9–14.
6. Geršl V, Hrdina R. Noninvasive polygraphic cardiac changes in daunorubicin – induced cardiomyopathy in rabbits. Sbor Ved Prac LFUK Hradec Králové 1994; 37:49–55.
7. Geršl V, Bajgar J, Krs O et al. Changes of some biochemical and hematological parameters following administration of daunorubicin in rabbits. Sbor Ved Prac LFUK Hradec Králové 1995; 38:79–84.
8. Gibbs CL, Woolley G, Kotsanas G, Gibson WR. Cardiac energetics in daunorubicin- induced cardiomyopathy. J Mol Cell Cardiol 1984; 16:953–62. <https://doi.org/10.1016/S0022-2828(84)80031-0>
9. Goebel M, Kaplan E. Antracycline-induced cardiotoxicity. Oncology 1992; 15:198–204.
10. Holt DW. Pre-clinical application of markers of myocardial damage. In: Kaski JC, Holt DW, eds. Developments in Cardiovascular Medicine. Kluwe Academic Publishers 1998; 205:201–10.
11. Levine BS, Henry MC, Port CD, Rosen E. Preclinical toxicologic evaluation of ICRF-187 in dogs. Cancer Treat Rep 1980; 64:1211–5.
12. Link G, Tirosh, R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996; 127(3):272–8. <https://doi.org/10.1016/S0022-2143(96)90095-5>
13. Mair J. Progress in myocardial damage detection: new biochemical markers for clinicians. Crit Rev Clin Lab Sci 1997; 34(1):1–66. <https://doi.org/10.3109/10408369709038215>
14. Morjana NA. Degradation of human cardiac troponin I after myocardial infarction. Biotechnol Appl Biochem 1998; 28:105–11.
15. Nowak D, Drzenowski J. Antracycline-induced oxidative stress – its role in the development of cardiac damage. Cancer J 1996; 9:296–303.
16. O’Brien PJ, Dameron GW, Beck ML et al. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci 1997; 47(5):486–95.
17. O’Brien PJ, Dameron GW, Beck ML, Brandt M. Differential reactivity of cardiac and skeletal muscle from various species in two generations of cardiac troponin immunoassays. Res Vet Sci 1998; 65(2):135–7. <https://doi.org/10.1016/S0034-5288(98)90164-3>
18. Sinha BK. Cardiovascular Toxicology. Ed. Van Stee EW, New York: Raven Press, 1982.
19. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91(5):710–7. <https://doi.org/10.7326/0003-4819-91-5-710>
20. Von Hoff DD. Phase I trials of dexrazoxane and other potential applications for the agent. Semin Oncol 1998; 91:710–7.
21. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998; 56:385–403. <https://doi.org/10.2165/00003495-199856030-00009>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive